Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 12/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 12/20 | 0.55 |
| ▸ | GPR132 | Q9UNW8 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | GRN | P28799 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18196634 | 0.86 | TAS1R3 (0.48) | TAS1R3TAS1R1GPR132CA2 | |
| SCHEMBL4160485 | 0.81 | TAS1R3 (0.82) | TAS1R3TAS1R1CA2RAB9APPARG | |
| SCHEMBL18332904 | 0.81 | TAS1R3 (0.45) | TAS1R3TAS1R1GPR132CA2FOLH1 | |
| SCHEMBL11877343 | 0.77 | MAPK1 (0.62) | TAS1R3TAS1R1 | |
| SCHEMBL11877322 | 0.77 | MAPK1 (0.62) | TAS1R3TAS1R1 | |
| SCHEMBL18196739 | 0.76 | FOLH1 (0.40) | TAS1R3TAS1R1RAB9AFOLH1NPC1 | |
| SCHEMBL18803717 | 0.75 | CA2 (0.57) | TAS1R3TAS1R1CA2RAB9AFOLH1 | |
| SCHEMBL9829285 | 0.74 | RAB9A (0.60) | GPR132CA2RAB9AFOLH1NPC1 | |
| SCHEMBL3948327 | 0.74 | RAB9A (0.60) | GPR132CA2RAB9AFOLH1NPC1 | |
| SCHEMBL4168755 | 0.74 | TAS1R3 (0.83) | TAS1R3TAS1R1CA2GRNSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368878-A1 | REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | disclosed |
| US-20160319322-A1 | PATHOGEN DETECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368878-A1 | REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS | HAMP, SLC40A1, FTH1 | TAS1R3 3866/4885TAS1R1 4224/4885GPR132 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.